A girl holds a small bottle labeled with a “Vaccine COVID-19” sticker and a medical syringe on this illustration taken April 10, 2020.
Dado Ruvic | Reuters
Novavax on Thursday began a late-stage trial of its experimental Covid-19 vaccine in partnership with the UK authorities’s Vaccines Taskforce, sending the corporate’s shares up 6% after the bell.
The trial is predicted to enroll and take a look at the vaccine in as much as 10,000 contributors aged between 18 and 84 years over the subsequent 4 to 6 weeks.
Knowledge from the trial will assist regulatory submissions for license within the UK, EU and different nations, the corporate mentioned.
The research has two principal objectives, the primary incidence of PCR-confirmed symptomatic Covid-19 at the least 7 days after the second research vaccination in volunteers who haven’t been beforehand contaminated with SARS-CoV-2. The second principal purpose is first incidence of PCR-confirmed symptomatic reasonable or extreme Covid-19 at the least 7 days after the second research vaccination in volunteers who haven’t been beforehand contaminated with the virus.
The trial will enroll at the least 25% of contributors over the age of 65 and prioritize teams most affected by the Covid-19, the corporate mentioned.